51. Scleroderma Clinical trials / Disease details
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2004-002799-41-GB (EUCTR) | 15/08/2007 | 29/06/2005 | Iontophoresis as a possible therapy for digital ischaemia - preliminary studies in patients with scleroderma spectrum disorders - Vasodilator iontophoresis as a possible therapy for digital ischaemia | Iontophoresis as a possible therapy for digital ischaemia - preliminary studies in patients with scleroderma spectrum disorders - Vasodilator iontophoresis as a possible therapy for digital ischaemia | Digital ischaemia/ulceration in patients with scleroderma-spectrum disorders | Trade Name: NON PROPIETRY, THEREFORE N/A Product Name: SODIUM NITROPRUSSIDE | Salford Royal Hospitals Trust | UNIVERSITY OF MANCHESTER | Not Recruiting | Female: yes Male: yes | 6 | Phase 2 | United Kingdom |